Company Overview

Genovis’ business concept is to offer customers in the pharmaceutical and medical device industries tools that facilitate and save time in the development of new treatment methods and diagnostics. 

Genovis continues to launch new enzymes and product formats to meet the needs of the pharmaceutical companies. The unique portfolio of reagents and technologies offered by the Genovis Group is used by industry-leading and global pharmaceutical companies in research, analytical characterization, process development and quality control. Two product portfolios can be found within the Genovis Group: SmartEnzymes and Antibodies & Services. Researchers use SmartEnzymes to analyze biological drugs and to generate new molecules with defined attributes. Genovis Inc offers Antibodies & Services based on 30 years of experience developing the best antibodies for the research market, diagnostics and as tools for therapeutic antibody development.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (USA). Genovis shares are listed on Nasdaq First North Growth Market. The Company’s Certified Adviser is Carnegie Investment Bank AB (publ), phone: +46 (0)73 856 42 65, email: certifiedadviser@carnegie.se.